Impact of Extrahepatic Metastases on Overall Survival in Patients with Advanced Liver Dominant Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial.
Hepatocellular carcinoma
Metastases
Prognosis
Sorafenib
Journal
Liver cancer
ISSN: 2235-1795
Titre abrégé: Liver Cancer
Pays: Switzerland
ID NLM: 101597993
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
21
02
2020
accepted:
28
07
2020
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
15
1
2021
Statut:
ppublish
Résumé
Extrahepatic spread is reported as a prognostic factor in patients with advanced hepatocellular carcinoma (HCC) receiving systemic therapy. However, clinical studies have reported conflicting results for the clinical impact of the pattern of tumor progression during treatment and the role of new extrahepatic metastases in length of survival. To evaluate the impact of extrahepatic metastases on survival in patients with HCC treated with sorafenib or with a combination of sorafenib and selective internal radiation treatment (SIRT). SORAMIC is a randomized, controlled trial comprising diagnostic, local ablation, and palliative cohorts. In the palliative cohort, patients not eligible for transarterial chemoembolization (TACE) were randomized 11:10 to SIRT plus sorafenib (SIRT + sorafenib) or sorafenib alone. This exploratory subanalysis evaluated the impact of extrahepatic metastases on survival. In the intent-to-treat cohort, 216 patients were randomized to SIRT + sorafenib and 208 to sorafenib alone. Seventeen patients with distant organ metastases (bone, This subanalysis of the SORAMIC trial suggests that in patients with liver-dominant advanced HCC, metastases to distant organs with the exception of pulmonary metastases do not in general exert a negative impact on patient prognosis. The choice of palliative treatment should incorporate a personalized analysis of the pattern of tumor distribution.
Identifiants
pubmed: 33442545
doi: 10.1159/000510798
pii: lic-0009-0771
pmc: PMC7768116
doi:
Types de publication
Journal Article
Langues
eng
Pagination
771-786Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
K.S.: Personal fees − Bayer. R.S.: Nothing to disclose. M.P.F.: Nothing to disclose. M.M.: Nothing to disclose. C.K.: Nothing to disclose. R.I.: Nothing to disclose. O.Ö.: Nothing to disclose. M.P.: Grants − Sirtex and Bayer; personal fees − Sirtex. B.P.: Nothing to disclose. M.S.: Personal fees − Bayer and Sirtex. R.S.: Nothing to disclose. D.P.: Grants − Sirtex and Bayer; personal fees − Sirtex and Bayer; and nonfinancial support − Sirtex. J.-P.B.: Grants − Bayer; personal fees − Bayer. P.R.: Nothing to disclose. P.M.: Nothing to disclose. J.R.: Grants − Sirtex and Bayer; personal fees − Sirtex and Bayer.
Références
PLoS One. 2015 Apr 29;10(4):e0124434
pubmed: 25923439
Radiology. 2000 Sep;216(3):698-703
pubmed: 10966697
Clin Radiol. 2003 May;58(5):372-7
pubmed: 12727165
J Hepatol. 2017 Jul;67(1):173-183
pubmed: 28323121
Dig Dis. 2009;27(2):80-92
pubmed: 19546545
Cancer. 2011 Oct 1;117(19):4475-83
pubmed: 21437884
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Hepatol. 2015 May;62(5):1112-21
pubmed: 25514557
Clin Radiol. 1996 Mar;51(3):160-6
pubmed: 8605744
Liver Int. 2008 Nov;28(9):1256-63
pubmed: 18710423
Hepatology. 2005 Nov;42(5):1208-36
pubmed: 16250051
Digestion. 2013;87(3):147-59
pubmed: 23548687
J Hepatol. 2019 Dec;71(6):1164-1174
pubmed: 31421157
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Dig Dis. 2011;29(3):333-8
pubmed: 21829026
PLoS One. 2018 Nov 30;13(11):e0207479
pubmed: 30500848
Hepatology. 2013 Dec;58(6):2023-31
pubmed: 23787822
Gut. 2020 Jan;69(1):168-176
pubmed: 30878947
J Hepatol. 2017 Nov;67(5):999-1008
pubmed: 28687477
J Cancer. 2017 Jul 21;8(12):2312-2318
pubmed: 28819435
Gastroenterology. 2019 Jan;156(2):477-491.e1
pubmed: 30367835
Hepatology. 2012 May;55(5):1432-42
pubmed: 22109811
Hepatology. 2015 Sep;62(3):784-91
pubmed: 25645399
HPB (Oxford). 2016 May;18(5):411-8
pubmed: 27154804
Cancer Med. 2018 Sep;7(9):4475-4484
pubmed: 30117307
Invest New Drugs. 2016 Apr;34(2):255-60
pubmed: 26769245
World J Gastroenterol. 2007 Jan 21;13(3):414-20
pubmed: 17230611
Hepatology. 2018 Jan;67(1):422-435
pubmed: 28881497
Medicine (Baltimore). 2017 Apr;96(17):e6745
pubmed: 28445298
Hepatology. 2018 May;67(5):1784-1796
pubmed: 29159910
Medicine (Baltimore). 2015 Apr;94(14):e688
pubmed: 25860213
J Gastroenterol Hepatol. 2012 Apr;27(4):684-9
pubmed: 21916984
J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6
pubmed: 23632345
J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7
pubmed: 16246200